US to propose rule scrutinizing outbound biotech licensing deals with China

The U.S. is set to propose a rule that would add scrutiny to outbound licensing deals between U.S. and Chinese biotech firms, signaling a tightening of technology transfer controls. The scope and specific terms remain unclear, but this marks a potential expansion of export controls into the biotech sector. This matters as it could disrupt cross-border R&D partnerships and affect biotech companies' access to the Chinese market.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works